The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer

Edyta Leśniak; Emilia Stec-Martyna; Daria Domańska-Senderowska; Hanna Romanowicz; Tomasz Krawczyk; Jan Bieńkiewicz; Andrzej Malinowski; Miłosz Wilczyński

doi:10.5114/pm.2024.145949

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Online First About the journal Editorial board Abstracting and indexing Subscription Contact Ethical standards and procedures Special Issues Instructions for authors Publication charge

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

4/2024
vol. 23

Send email

Copy url:

abstract:

Original paper

The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer

Edyta Leśniak

¹

,

Emilia Stec-Martyna

²

,

Daria Domańska-Senderowska

³

,

Hanna Romanowicz

⁴

,

Tomasz Krawczyk

⁴

,

Jan Bieńkiewicz

¹

,

Andrzej Malinowski

¹

,

Miłosz Wilczyński

^{5, 6}

Department of Operative Gynecology, Endoscopy and Gynecologic Oncology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
Central Scientific Laboratory CoreLab, Medical University of Lodz, Lodz, Poland
Department of Biomedicine and Genetics, Medical University of Lodz, Lodz, Poland
Department of Pathology, Polish Mother’s Memorial Hospital Research Institute, Lodz, Poland
Department of Surgical and Endoscopic Gynecology, Medical University of Lodz, Lodz,
Department of Surgical, Endoscopic and Gynecological Oncology, Polish Mother’s Health Center-Research Institute, Lodz, Poland

Menopause Rev 2024; 23(4): 180-184

DOI: https://doi.org/10.5114/pm.2024.145949

Online publish date: 2024/12/22

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Leśniak E, Stec-Martyna E, Domańska-Senderowska D, et al. The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer. Menopause Review/Przegląd Menopauzalny. 2024;23(4):180-184. doi:10.5114/pm.2024.145949.

APA

Leśniak, E., Stec-Martyna, E., Domańska-Senderowska, D., Romanowicz, H., Krawczyk, T.,  & Bieńkiewicz, J. et al. (2024). The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer. Menopause Review/Przegląd Menopauzalny, 23(4), 180-184. https://doi.org/10.5114/pm.2024.145949

Chicago

Leśniak, Edyta, Emilia Stec-Martyna, Daria Domańska-Senderowska, Hanna Romanowicz, Tomasz Krawczyk, Jan Bieńkiewicz,  and Andrzej Malinowski et al. 2024. "The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer". Menopause Review/Przegląd Menopauzalny 23 (4): 180-184. doi:10.5114/pm.2024.145949.

Harvard

Leśniak, E., Stec-Martyna, E., Domańska-Senderowska, D., Romanowicz, H., Krawczyk, T., Bieńkiewicz, J., Malinowski, A.,  and Wilczyński, M. (2024). The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer. Menopause Review/Przegląd Menopauzalny, 23(4), pp.180-184. https://doi.org/10.5114/pm.2024.145949

MLA

Leśniak, Edyta et al. "The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer." Menopause Review/Przegląd Menopauzalny, vol. 23, no. 4, 2024, pp. 180-184. doi:10.5114/pm.2024.145949.

Vancouver

Leśniak E, Stec-Martyna E, Domańska-Senderowska D, Romanowicz H, Krawczyk T, Bieńkiewicz J et al. The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer. Menopause Review/Przegląd Menopauzalny. 2024;23(4):180-184. doi:10.5114/pm.2024.145949.

PlumX metrics:

Introduction:
Ovarian cancer is a significant cause of death among females. MiRNAs, particularly the miR-196 family, can influence tumor progression by targeting specific pathways. Detecting ovarian cancer early is challenging, highlighting the need for additional biomarkers such as miRNAs to improve diagnosis and treatment strategies.

Material and methods:
Healthy controls and patients with high-grade serous carcinoma (n = 50) were recruited for this study. Samples for testing were obtained from archival paraffin blocks obtained from intraoperative material.

Results:
The study found that miRNA 196a expression was significantly elevated in ovarian cancer patients compared to the control group (p < 0.05). Higher miRNA 196a expression was also noted in patients with advanced FIGO stages (III, IV). Increased miRNA expression was significantly associated with higher mortality and chemoresistance (p < 0.05). Genotype analysis revealed differing distributions of SNPs (C/C, C/T, T/T) between the study and control groups, but no significant correlation with malignancy was observed.

Conclusions:
This study supports the critical role of microRNA-196a in the progression of ovarian cancer.

keywords:

The clinicopathological role of miRNA-196a and its SNP variant rs11614913 in high‑grade ovarian cancer

Edyta Leśniak 1 , Emilia Stec-Martyna 2 , Daria Domańska-Senderowska 3 , Hanna Romanowicz 4 , Tomasz Krawczyk 4 , Jan Bieńkiewicz 1 , Andrzej Malinowski 1 , Miłosz Wilczyński 5, 6

biomarkers, polymorphisms, ovarian cancer, miRNA, oncogenesis

Edyta Leśniak

¹

,

Emilia Stec-Martyna

²

,

Daria Domańska-Senderowska

³

,

Hanna Romanowicz

⁴

,

Tomasz Krawczyk

⁴

,

Jan Bieńkiewicz

¹

,

Andrzej Malinowski

¹

,

Miłosz Wilczyński

^{5, 6}